natgillin/translations-raw huggingface dataset:
As a result of Numient's pharmacokinetic characteristics, the doses and dosing frequency of Numient are not directly interchangeable with those of other levodopa/DDC inhibitor immediate release medicinal products (see section 5.2).
Zbog farmakokinetičkih svojstava Numienta, doze i učestalost doziranja Numienta nisu izravno međusobno zamjenjivi s drugim lijekovima s trenutnim oslobađanjem koji sadrže levodopu/DDC inhibitor (vidjeti dio 5.2).
Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits.
Levodopa, kao i kombinacije karbidope i levodope, izazvale su visceralne i koštane malformacije u kunića.
The pharmacokinetics of Numient were evaluated following single doses in healthy subjects and following single and multiple doses in patients with Parkinson's disease.
Numienta procijenjena je nakon pojedinačnih doza u zdravih ispitanika i nakon pojedinačnih i višestrukih doza u bolesnika oboljelih od Parkinsonove bolesti.
Breast-feeding should be discontinued during treatment with Numient.
Dojenje treba prekinuti tijekom liječenja Numientom.
if you are allergic to levodopa or carbidopa, or any of the other ingredients of this medicine (listed in section 6); if you have narrow-angle glaucoma (an eye disorder); if you have phaeochromocytoma (a rare tumour of the adrenal gland); if you are taking certain medicines for treating depression [non-selective monoamine oxidase (MAO) inhibitors].
ako ste alergični na levodopu ili karbidopu ili neki drugi sastojak ovog lijeka (naveden u dijelu ako imate glaukom uskog kuta (poremećaj oka); ako imate feokromocitom (rijetki tumor nadbubrežne žlijezde); ako uzimate neke lijekove za liječenje depresije [neselektivne inhibitore monoaminooksidaze (MAO)].
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE/HDPE
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU BOCA/HDPE
How to take Numient
Kako uzimati Numient
Dose adjustment of the antihypertensive medicinal products may be required during the titration phase of treatment with this modified-release levodopa/carbidopa medicinal product.
Može biti potrebna prilagodba doze antihipertenzivnih lijekova tijekom faze titracije liječenja ovim lijekom s prilagođenim oslobađanjem levodope/karbidope.
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa (see section 4.4).
Patološko kockanje, povećani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se pojaviti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima koja sadrže levodopu (vidjeti dio 4.4).
These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings.
Ta se ponašanja nazivaju poremećaji kontrole impulsa i mogu uključivati ovisnost o kockanju, pretjerano jedenje ili rastrošnost, neuobičajeno jaki seksualni poriv ili učestale misli ili osjećaje vezane uz spolni odnos.
Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more levodopa available for delivery to the brain.
Budući da je njena aktivnost inhibicije dekarboksilaze ograničena na ekstracerebralna tkiva, primjena karbidope s levodopom omogućava veću raspodjelu levodope u mozak.
Syncope, thrombophlebitis
sinkopa, tromboflebitis
Initial total daily dose of Numient (levodopa in mg)
Početna ukupna dnevna doza Numienta (levodopa u mg)
The initial total daily dose of Numient described in Table 1 above may need to be decreased by approximately 30% for patients converting specifically from levodopa/DDC inhibitor modified-release medicinal products to Numient.
Početnu ukupnu dnevnu dozu Numienta opisanu u gore navedenoj Tablici 1 može biti potrebno smanjiti za otprilike 30 % za bolesnike koji izričito prelaze s lijekova s prilagođenim oslobađanjem koji sadrže levodopu/DDC inhibitor na Numient.
Patients with a major psychotic disorder or a history of psychotic disorder must be treated cautiously with levodopa/carbidopa because of the risk of exacerbating psychosis.
Bolesnici sa značajnim psihotičnim poremećajem ili anamnezom psihotičnog poremećaja moraju biti oprezno liječeni levodopom/karbidopom zbog rizika od egzacerbacije psihoze.
Non-selective monoamine oxidase inhibitors must be discontinued at least 2 weeks prior to treatment initiation with the modified-release levodopa/carbidopa capsule medicinal product (see section 4.3).
Uzimanje neselektivnih inhibitora monoaminoksidaze mora se prekinuti najmanje 2 tjedna prije uvođenja liječenja kapsulama lijeka s prilagođenim oslobađanjem levodope/karbidope (vidjeti dio 4.3).
Serious events of gastrointestinal haemorrhage (uncommon) and of allergic oedema (uncommon) were reported in the clinical studies with Numient.
Ozbiljni događaji gastrointestinalnog krvarenja (manje često) i alergijskog edema (manje često) prijavljeni su u kliničkim ispitivanjima s Numientom.
Following multiple dosing in patients, modified-release levodopa/carbidopa had reduced fluctuations in levodopa plasma concentrations with peak-to-trough fluctuation index of 1.5 with minimal accumulation of levodopa.
Nakon višestrukog doziranja u bolesnika, levodopa/karbidopa s prilagođenim oslobađanjem smanjila je fluktuacije u koncentraciji levodope u plazmi s indeksom fluktuacije od vršne do najniže vrijednosti koncentracije lijeka od 1,5 s minimalnim nakupljanjem levodope.
Certain side effects such as sleepiness and dizziness that have been reported with this modified-release levodopa/carbidopa capsule medicinal product may affect some patients' ability to drive or operate machinery.
Određene nuspojave kao što su pospanost i omaglica koje su prijavljene kod ovih kapsula lijeka s prilagođenim oslobađanjem levodope/karbidope mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima u nekih bolesnika.
Therefore, you must refrain from driving or engaging in activities where impaired alertness may put yourself or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved.
Stoga se morate suzdržati od upravljanja vozilima ili sudjelovanja u aktivnostima gdje nedostatak budnosti može dovesti Vas ili druge u opasnost od ozbiljne ozljede ili smrti (npr. upravljanje strojevima) dok se navedeni ponavljajući napadaji sna i izrazita pospanost ne prestanu javljati.
Opaque, white, high-density polyethylene (HDPE) bottle with polypropylene screw closure.
Neprozirna, bijela boca od polietilena visoke gustoće (HDPE) s polipropilenskim zatvaračem na navoj.
In healthy adults, oral administration of the modified-release levodopa/carbidopa medicinal product after a high-fat, high-calorie meal reduced levodopa Cmax by 21%.
U zdravih odraslih osoba, primjena lijeka s prilagođenim oslobađanjem levodope/karbidope kroz usta nakon visokokaloričnog obroka s visokim udjelom masnoće smanjila je Cmax levodope za 21 %.
Dark saliva, bruxism, hiccups, sialorrhoea
tamna slina, bruksizam, štucavica, sijaloreja
Anticholinergic medicinal products may impair the effect of levodopa, due to a delayed absorption.
Antikolinergički lijekovi mogu pogoršati učinak levodope zbog odgođene apsorpcije.
In healthy adults, oral administration of Numient after a high-fat, high-calorie meal reduced levodopa Cmax 21% while the overall extent of absorption of levodopa (AUCinf) was similar (13% increase) to that observed in the fasted state (see section 5.2).
U zdravih odraslih osoba, primjena Numienta kroz usta nakon visokokaloričnog obroka s visokim udjelom masnoće smanjila je Cmax levodope za 21 %, dok je ukupni opseg apsorpcije levodope (AUCinf) bio sličan (13 % povećanja) zapaženom natašte (vidjeti dio 5.2).
The dose of levodopa may need to be reduced when an MAO inhibitor selective for type B is added.
Dozu levodope možda će trebati smanjiti kada se dodaje inhibitor MAO za tip B.
A previous history of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.
Ranija anamneza neuroleptičkog malignog sindroma (NMS) i/ili netraumatske rabdomiolize.
Unchanged levodopa accounts for less than 10% of the total urinary excretion.
Nepromijenjena levodopa iznosi manje od 10 % ukupnog izlučivanja mokraćom.
Swallow whole, do not chew.
Progutati cijele, ne žvakati.
Eligible patients were randomized (1:1:1:1) to placebo or one of three fixed levodopa/carbidopa doses of 145 mg/36.25 mg, 245 mg/61.25 mg, or 390 mg/97.5 mg, three times a day.
Podobni bolesnici randomizirani su (1:1:1:1) u placebo ili u jednu od tri fiksne doze levodope/karbidope od 145 mg/36,25 mg, 245 mg/61,25 mg ili 390 mg/97,5 mg, tri puta dnevno.
Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on levodopa or levodopa/carbidopa therapy.
Nužan je oprez pri interpretaciji razina kateholamina i njihovih metabolita u plazmi i mokraći u bolesnika na terapiji levodopom ili levodopom/karbidopom.
Dose recommendations should be followed at initiation of treatment and adapted according to clinical response.
Pri uvođenju liječenja potrebno je pratiti preporuke za dozu i prilagoditi ju u skladu s kliničkim odgovorom.
Numient is used to improve the symptoms of Parkinson's disease in adults.
Numient se koristi za ublažavanje simptoma Parkinsonove bolesti u odraslih.
Inhibition or induction effects of levodopa and carbidopa have not been investigated.
Učinci inhibicije ili indukcije levodope i karbidope nisu ispitivani.
It is recommended to monitor patients for the onset or evolution of dyskinesia and to adjust levodopa/carbidopa doses accordingly.
Preporučuje se pratiti bolesnike zbog pojave ili razvoja diskinezije i u skladu s tim prilagoditi doze levodope/karbidope.
Symptomatic treatment of adult patients with Parkinson's disease.
Simptomatsko liječenje odraslih bolesnika oboljelih od Parkinsonove bolesti.
There are no studies on the pharmacokinetics of levodopa and carbidopa when administered as Numient in children.
Ne postoje ispitivanja farmakokinetike levodope i karbidope kada se primjenjuju kao Numient u djece.
In patients with Parkinson's disease, multiple-dose pharmacokinetics was comparable to single-dose pharmacokinetics, i.e. there was a minimal accumulation of levodopa from the modified-release levodopa/carbidopa medicinal product.
U bolesnika s Parkinsonovom bolešću, farmakokinetike višestrukih doza usporedive su s farmakokinetikom pojedinačnih doza, tj. postojalo je minimalno nakupljanje levodope iz lijeka s prilagođenim oslobađanjem levodope/karbidope.
The acute symptoms of levodopa/DDC inhibitor overdose can be expected to arise from dopaminergic overstimulation.
Akutni simptomi predoziranja levodopom/DDC inhibitorom mogu se očekivati da nastanu zbog pretjerane dopaminergičke stimulacije.
950 to 1249
950 do 1249
Women should not breast-feed during treatment with Numient.
Žene ne smiju dojiti tijekom liječenja Numientom.
Check with your doctor or pharmacist if you are not sure
Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni Vaš će Vam liječnik reći koliko točno kapsula
Feeling sick to your stomach (nausea)
osjećaj mučnine u želucu
Patients should be maintained on the lowest dose required to achieve symptomatic control and to minimize adverse reactions such as dyskinesia and nausea.
Bolesnike treba održavati na najnižoj potrebnoj dozi kako bi se postigla kontrola simptoma i umanjile nuspojave kao što su diskinezija i mučnina.
Amneal Pharma logo
Amneal Pharma Europe
Neurological findings, including muscle rigidity, involuntary movements, altered consciousness, mental status changes; other disturbances, such as autonomic dysfunction, tachycardia, tachypnoea, sweating, hyper- or hypotension; laboratory findings, such as creatine phosphokinase elevation, leucocytosis, myoglobinuria, and increased serum myoglobin have been reported.
Prijavljeni su neurološki nalazi, uključujući ukočenost mišića, nevoljne pokrete, izmijenjenu svijest, promjene mentalnog statusa; drugi poremećaji, kao što su autonomna disfunkcija, tahikardija, tahipneja, znojenje, hipertenzija ili hipotenzija; laboratorijski nalazi, kao što su povišena kreatin fosfokinaza, leukocitoza, mioglobinurija i povišeni mioglobin u serumu.
There are no studies on the pharmacokinetics of levodopa and carbidopa in patients with hepatic impairment (see section 4.2).
Ne postoje ispitivanja farmakokinetike levodope i karbidope u bolesnika s oštećenjem jetre (vidjeti dio 4.2).
Carbidopa permits more levodopa to reach the brain and more dopamine to be formed increasing the risk for certain adverse CNS reactions including dyskinesia.
Karbidopa omogućuje da više levodope dođe do mozga i stvaranje više dopamina povećavajući rizik od nekih nuspojava SŽS-a, uključujući diskineziju.
Impact of renal function on levodopa/carbidopa clearance is limited (see section 5.2).
Utjecaj bubrežne funkcije na klirens levodope/karbidope ograničen je (vidjeti dio 5.2).
Alternatively, for patients that have difficulty swallowing a capsule, this medicinal product may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (e.g., 2 tablespoons) of soft food such as apple sauce, yoghurt, or pudding.
Alternativno, za bolesnike koji imaju poteškoća pri gutanju kapsule, ovaj lijek može se primijeniti pažljivim otvaranjem kapsule i posipanjem čitavog sadržaja na malu količinu (npr. 2 velike žlice) mekane hrane kao što je kaša od jabuka, jogurt ili puding.
Co-administration with non-selective monoamine oxidase (MAO) inhibitors.
Istovremena primjena neselektivnih inhibitora monoaminoksidaze (MAO).
What you need to know before you take Numient Do not take Numient:
Što morate znati prije nego počnete uzimati Numient
Store the medicine in the original package, in order to protect from light and moisture.
Čuvati lijek u originalnom pakiranju radi zaštite od svjetlosti i vlage.
Talk to your doctor or pharmacist before taking Numient if you have, have ever had, or develop: sudden sleep attacks or sometimes feel very sleepy any form of severe mental disorder like psychosis feelings of depression, suicidal thoughts, or notice unusual changes in your behaviour tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure, or notice that your muscles get very rigid or jerk violently.
Obratite se svom liječniku ili ljekarniku prije nego uzmete Numient ako imate, ako ste ikada imali ili dobijete: napadaje iznenadnog nastupa sna ili se ponekad osjećate jako pospani bilo kakav oblik teškog mentalnog poremećaja kao što je psihoza osjećaje depresije, pomisli na samoubojstvo ili primijetite neobične promjene ponašanja nevoljna drhtanja, uznemirenost, smetenost, vrućicu, ubrzan puls ili izrazite promjene krvnog tlaka ili primijetite da vam mišići postanu jako ukočeni ili se snažno trzaju.
Levodopa/carbidopa can cause orthostatic hypotension.
Levodopa/karbidopa može izazvati ortostatsku hipotenziju.
Interruption of therapy
Prekid terapije
For comparable doses, Numient results in a levodopa peak concentration (Cmax) that is 30% that of immediate-release levodopa/carbidopa.
Za usporedive doze, Numient dovodi do vršne koncentracije levodope (Cmax) koja iznosi 30 % od one postignute lijekom s trenutnim oslobađanjem levodope/karbidope.
Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor.
Karbidopa je periferni inhibitor dekarboksilaze aromatskih aminokiselina.
Mean UPDRS (Part II and Part III) Score a)
Srednja vrijednost rezultata UPDRS-a (dio II i dio III)
SB-6018 blue ink Shellac (E904) Propylene glycol Indigo carmine (E132), lake
SB-6018 plava tinta šelak (E904) propilenglikol indigo karmin (E132), lake
Next, patients were randomized to a double-blind, 13-week study treatment period of either optimized immediate release levodopa/carbidopa treatment or Numient.
Nadalje, bolesnici su bili randomizirani u dvostruko slijepi, 13-tjedni period liječenja ili optimiziranim liječenjem levodopom/karbidopom s trenutnim oslobađanjem ili Numientom.
Patients receiving the modified-release levodopa/carbidopa medicinal product initiated treatment at 95 mg levodopa/23.75 mg carbidopa three times daily (TID).
Bolesnici koji primaju lijekove s prilagođenim oslobađanjem levodope/karbidope počeli su liječenje s 95 mg levodope/23,75 mg karbidope tri puta dnevno (TID).
How to store Numient
Kako čuvati Numient
There is limited experience with a total daily dose of more than 1,170 mg of levodopa when administered in levodopa-naïve patients.
Iskustvo s ukupnom dnevnom dozom višom od 1170 mg levodope primijenjenom u bolesnika koji nisu liječeni levodopom je ograničeno.
The ADVANCE-PD study was a 22-week study consisting of a 3-week dose adjustment of pre-study immediate release levodopa/carbidopa treatment prior to a 6-week conversion to Numient.
Ispitivanje ADVANCE-PD bilo je ispitivanje u trajanju od 22 tjedna koje se sastojalo od 3 tjedna prilagodbe doze prethodnog liječenja levodopom/karbidopom s trenutnim oslobađanjem prije 6tjednog prijelaza na Numient.
Phenytoin and papaverine
Fenitoin i papaverin
Levodopa competes with certain amino acids for transport, therefore high protein meals may impair the absorption of levodopa.
Levodopa se natječe s nekim aminokiselinama za prijenos, stoga visokoproteinski obroci mogu umanjiti apsorpciju levodope.
Management of acute overdose with levodopa/DDC preparations is the same as management of acute overdose with levodopa.
Zbrinjavanje akutnog predoziranja preparatima levodope/ DDC inhibitora jednako je zbrinjavanju akutnog predoziranja levodopom.
b) Combined term that includes atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block, sick sinus syndrome, bradycardia, and tachycardia
b) Kombinirani termin koji uključuje fibrilaciju atrija, undulaciju atrija, atrioventrikularni blok, blok grane, sindrom bolesnog sinusa,
Your doctor will tell you exactly how many capsules of Numient to take each day If you have never had levodopa before, the usual starting dose for Numient is one 95 mg capsule three times a day for three days.
Ako nikada prije niste uzimali levodopu, uobičajena početna doza za Numient je jedna kapsula od 95 mg tri puta dnevno kroz tri dana.
The bioavailability of carbidopa from this medicinal product relative to immediate release levodopa and carbidopa tablets was approximately 50%.
Bioraspoloživost karbidope iz tog lijeka u odnosu na tablete levodope/karbidope s trenutnim oslobađanjem bila je otprilike 50 %.
Modified-release levodopa/carbidopa may be used together with other medicinal products for the treatment of Parkinson's disease.
Levodopa/karbidopa s prilagođenim oslobađanjem se smije primjenjivati zajedno s drugim lijekovima za liječenje Parkinsonove bolesti.
A symptom complex resembling neuroleptic malignant syndrome and rhabdomyolysis may occur with levodopa/carbidopa medicinal products, although no cases have been identified in clinical studies with Numient.
Kompleks simptoma koji nalikuju neuroleptičkom malignom sindromu i rabdomiolizi mogu se pojaviti kod primjene lijekova koji sadrže levodopu/karbidopu, iako takvi slučajevi nisu ustanovljeni u kliničkim ispitivanjima s Numientom.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating, and dopamine dysregulation syndrome can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa.
Bolesnici i njegovatelji moraju biti svjesni da simptomi ponašanja poremećaja kontrole impulsa uključuju patološko kockanje, povećani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje, a može se pojaviti i sindrom poremećene regulacije dopamina u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima koja sadrže levodopu.
Orthostatic hypotension (see section 4.4 and 4.9), hypertension (see section
Krvožilni poremećaji ortostatska hipotenzija (vidjeti dijelove 4.4 i 4.9), hipertenzija (vidjeti dio 4.5)
Alternatively, if you have difficulty swallowing a capsule, this medicine may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (e.g., 2 tablespoons) of soft food such as apple sauce, yoghurt, or pudding.
Ako imate poteškoća pri gutanju kapsule, ovaj se lijek može primjenjivati pažljivim otvaranjem kapsule i posipanjem čitavog sadržaja na malu količinu (npr. 2 velike žlice) mekane hrane kao što je kaša od jabuka, jogurt ili puding.
Change from baseline at week 30 (or at early termination)c)
Promjena od početne vrijednosti u 30. tjednu (ili kod ranog prekida)
There is a recognized drug-drug interaction of levodopa with type B MAO inhibitors which potentiates the effects of levodopa.
Potvrđena je reakcija između lijeka levodope i MAO inhibitora tip B što naglašava učinke levodope.
The safety and efficacy of Numient in patients under 18 years of age have not been studied
Sigurnost i djelotvornost Numienta u bolesnika mlađih od 18 godina nije ispitivana.
The other ingredients are cellulose, microcrystalline, mannitol, tartaric acid, ethylcellulose, hypromellose, sodium starch glycolate, sodium laurilsulfate, povidone, talc, methacrylic acidmethyl methacrylate copolymers (1:1), methacrylic acid - methyl methacrylate copolymers (1:2), triethyl citrate, croscarmellose sodium and magnesium stearate
Ostali sastojci su mikrokristalična celuloza, manitol, tartarična kiselina, etilceluloza, hipromeloza, natrijev škrobni glikolat, natrijev lauril sulfat, povidon, talk, metakrilna kiselinametil metakrilat kopolimeri (1:1), metakrilna kiselina - metil metakrilat kopolimeri (1:2), trietil citrat, umrežena karmelozanatrij i magnezijev stearat
When converting patients from levodopa/DDC inhibitor medicinal products to Numient, the dose should be adjusted to maintain sufficient symptomatic control.
Kada bolesnici prelaze s lijekova koji sadrže levodopu/DDC inhibitor na Numient, potrebno je prilagoditi dozu kako bi se održala dovoljna kontrola simptoma.
The bioavailability of levodopa from Numient in patients was approximately 70% relative to immediate release levodopa/carbidopa.
Bioraspoloživost levodope iz Numienta u bolesnika bila je otprilike 70 % u odnosu na levodopu/karbidopu s trenutnim oslobađanjem.
400 to 549
400 do 549
For patients currently treated with other levodopa/DDC inhibitor modified-release medicinal products, limited information regarding conversion to Numient is available.
Za bolesnike koji se trenutno liječe drugim lijekovima s prilagođenim oslobađanjem koji sadrže levodopu/DDC inhibitor, dostupne su ograničene informacije koje se odnose na prelazak na Numient.
Decreased appetite, weight increase
Poremećaji metabolizma i prehrane smanjenje težine smanjen apetit, povećanje težine
Initial dose and titration in levodopa-naïve patients
Početna doza i titracija u bolesnika koji nisu liječeni levodopom
Levodopa/carbidopa should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of peptic ulcer disease (because of the possibility of upper gastro-intestinal haemorrhage) and a history of convulsions.
Levodopu/karbidopu treba primjenjivati uz oprez u bolesnika s ishemijskom bolešću srca, teškom kardiovaskularnom ili plućnom bolešću, bronhalnom astmom, bubrežnom, jetrenom ili endokrinom bolešću, kao i u bolesnika s anamnezom peptičkog ulkusa (zbog mogućnosti hemoragije iz gornjeg gastrointestinalnog trakta) i konvulzija.
In vivo, co-administration of Numient with up to 40% volume-to-volume (v/v) alcohol did not result in dosedumping of levodopa or carbidopa.
In vivo istodobna primjena Numienta s alkoholom do 40 % volumenske koncentracije nije dovela do nakupljanja doze levodope ili karbidope.
Phaeochromocytoma.
Feokromocitom.